Shares of Glenmark Pharmaceuticals Ltd traded flat after touching a day’s high of Rs 1,846.90 on 11th November, even as the company announced that its wholly owned subsidiary, Glenmark Specialty S.A., has received approval from the National Medical Products Administration (NMPA) of China for RYALTRIS Compound Nasal Spray (GSP 301 NS) to treat allergic rhinitis (AR) in adults and children.

The approval covers moderate to severe seasonal allergic rhinitis in adults and children aged six years and above. It also covers mild to severe perennial allergic rhinitis in adults and children aged twelve years and above.

It was granted without any additional data requests, marking a key milestone in Glenmark’s respiratory portfolio. The company said this reflects its continued progress in developing innovative therapies for chronic conditions.

RYALTRIS is a first-of-its-kind fixed-dose nasal spray. It combines olopatadine hydrochloride (an antihistamine) and mometasone furoate (a corticosteroid) to treat allergic rhinitis symptoms.

It is Glenmark’s first globally commercialised speciality product, already approved in the US, EU, UK, Australia, South Korea, and Russia. In China, commercialisation will be handled by Grand Pharmaceuticals Group Limited under an exclusive licensing agreement.

The NMPA approval follows successful Phase III trials in China involving 535 patients. In these trials, RYALTRIS demonstrated superior efficacy compared with existing treatments. It also met all safety and tolerability benchmarks.

At 2:39 PM, shares of Glenmark were trading 0.57% lower at Rs 1,819.50 on NSE.

Unicorn Signals leverages advanced AI technology to provide you with powerful market predictions and actionable stock scans. Download the app today and 10x your trading & investing journey!